New inhaled therapy for lung blood pressure passes first safety hurdle

NCT ID NCT06429930

Recruiting now Disease control Sponsor: Pharmosa Biopharm Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage trial tests the safety of a single inhaled dose of L608 in 32 healthy volunteers. L608 is a liposomal formulation designed to treat pulmonary arterial hypertension, a condition of high blood pressure in the lungs. The study compares different doses against a placebo to check for side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L608 (liposomal inhalation suspension)
What this could lead to: If safe, this could lead to a new inhaled treatment for pulmonary arterial hypertension, offering a more targeted way to manage the disease.
What could go wrong: This is a very early Phase 1 safety study in only 32 healthy people, not patients. It tests low doses and may not show benefit or translate into an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung disorder pulmonary arterial hypertension pulmonary hypertension respiratory system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

NZCR Ltd (New Zealand Clinical Research)
RECRUITING

Christchurch, 8011, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.